Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. JCO 32:3048–3058. https://doi.org/10.1200/JCO.2013.53.5229

Article  Google Scholar 

Bednaruk-Młyński E, Pieńkowska J, Skórzak A, Małkowski B, Kulikowski W, Subocz E, Dzietczenia J, Zalewska M, Leśniewski-Kmak K, Zaucha R, Wróbel T, Zaucha JM (2015) Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of hodgkin lymphoma. Leuk Lymphoma 56:377–382. https://doi.org/10.3109/10428194.2014.919635

Article  PubMed  CAS  Google Scholar 

Bird D, Patel C, Scarsbrook AF, Cosgrove V, Thomas E, Gilson D, Prestwich RJD (2017) Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a pre-chemotherapy PET-CT in the radiotherapy treatment position. Radiother Oncol 124:161–167. https://doi.org/10.1016/j.radonc.2017.05.014

Article  PubMed  Google Scholar 

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck H‑J, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich H‑T, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie, Nordic Lymphoma Group, Australasian Leukaemia and Lymphoma Group (2024) Assessing the efficacy and tolerability of PET-guided brECADD versus eBEACOPP in advanced-stage, classical hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 404:341–352. https://doi.org/10.1016/S0140-6736(24)01315-1

Article  PubMed  CAS  Google Scholar 

Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A (2021) PET-guided omission of radiotherapy in early-stage unfavourable hodgkin lymphoma (GHSG HD 17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:223–234. https://doi.org/10.1016/S1470-2045(20)30601-X

Article  PubMed  CAS  Google Scholar 

Bos D, Guberina N, Zensen S, Opitz M, Forsting M, Wetter A (2023) Radiation exposure in computed tomography. Dtsch Ärztebl Int. https://doi.org/10.3238/arztebl.m2022.0395

Article  PubMed  PubMed Central  Google Scholar 

Casasnovas R‑O, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac A‑C, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker L‑M, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M (2019) PET-adapted treatment for newly diagnosed advanced hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 20:202–215. https://doi.org/10.1016/S1470-2045(18)30784-8

Article  PubMed  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. JCO 32:3059–3067. https://doi.org/10.1200/JCO.2013.54.8800

Article  Google Scholar 

Lemus DOM, Cao M, Cai B, Cummings M, Zheng D (2024) Adaptive radiotherapy: next-generation radiotherapy. Cancers 16:1206. https://doi.org/10.3390/cancers16061206

Article  Google Scholar 

Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu A‑L, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink H‑K, Müller R‑P, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable hodgkin’s lymphoma: final analysis of the German hodgkin study group HD11 trial. JCO 28:4199–4206. https://doi.org/10.1200/JCO.2010.29.8018

Article  Google Scholar 

Eich HT, Kriz J, Müller R‑P (2011) Evolution of radiation therapy within the German hodgkin study group trials. J Natl Compr Canc Netw 9:1073–1080. https://doi.org/10.6004/jnccn.2011.0088

Article  PubMed  CAS  Google Scholar 

Georgi TW, Stoevesandt D, Kurch L, Bartelt JM, Hasenclever D, Dittmann H, Ferda J, Francis P, Franzius C, Furth C, Gräfe D, Gussew A, Hüllner M, Menezes LJ, Mustafa M, Stegger L, Umutlu L, Zöphel K, Zucchetta P, Körholz D, Sabri O, Mauz-Körholz C, Kluge R (2023) Optimized whole-body PET MRI sequence workflow in pediatric hodgkin lymphoma patients. J Nucl Med 64:96–101. https://doi.org/10.2967/jnumed.122.264112

Article  PubMed  PubMed Central  CAS  Google Scholar 

Girinsky T, Aupérin A, Ribrag V, Elleuch M, Fermé C, Bonniaud G, Ruelle C, Alberini J‑L, Celebic A, Edeline V (2014) Role of FDG-PET in the implementation of involved-node radiation therapy for hodgkin lymphoma patients. Int J Radiat Oncol 89:1047–1052. https://doi.org/10.1016/j.ijrobp.2014.04.026

Article  Google Scholar 

Granata C, Sofia C, Francavilla M, Kardos M, Kasznia-Brown J, Nievelstein RA, Olteanu BS, Owens C, Salerno S, Sorantin E, Apine I (2025) Let’s talk about radiation dose and radiation protection in children. Pediatr Radiol 55:386–396. https://doi.org/10.1007/s00247-024-06009-0

Article  PubMed  Google Scholar 

Heacock L, Weissbrot J, Raad R, Campbell N, Friedman KP, Ponzo F, Chandarana H (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. Am J Roentgenol 204:842–848. https://doi.org/10.2214/AJR.14.13181

Article  Google Scholar 

van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C‑A, Kobe C (2022) Predictive value of baseline metabolic tumor volume in early-stage favorable hodgkin lymphoma—data from the prospective, multicenter phase III HD16 trial. BMC Cancer 22:672. https://doi.org/10.1186/s12885-022-09758-z

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heusch P, Buchbender C, Beiderwellen K, Nensa F, Hartung-Knemeyer V, Lauenstein TC, Bockisch A, Forsting M, Antoch G, Heusner TA (2013) Standardized uptake values for [18F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol 82:870–876. https://doi.org/10.1016/j.ejrad.2013.01.008

Article  PubMed  Google Scholar 

Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage hodgkin lymphoma. Eur J Haematol 78:206–212. https://doi.org/10.1111/j.1600-0609.2006.00802.x

Article  PubMed  Google Scholar 

Jakob T, Onkologie L (2022) S3-Leitlinie hodgkin lymphom

Google Scholar 

Mettler J, Müller H, Voltin C‑A, Baues C, Klaeser B, Moccia A, Borchmann P, Engert A, Kuhnert G, Drzezga AE, Dietlein M, Kobe C (2018) Metabolic tumour volume for response prediction in advanced-stage hodgkin lymphoma. J Nucl Med 60:207–211. https://doi.org/10.2967/jnumed.118.210047

Article  PubMed  CAS  Google Scholar 

Metwally H, Courbon F, David I, Filleron T, Blouet A, Rives M, Izar F, Zerdoud S, Plat G, Vial J, Robert A, Laprie A (2011) Coregistration of Prechemotherapy PET-CT for planning pediatric hodgkin’s disease radiotherapy significantly diminishes Interobserver variability of clinical target volume definition. Int J Radiat Oncol Biol Phys 80:793–799. https://doi.org/10.1016/j.ijrobp.2010.02.024

Article  PubMed  Google Scholar 

Pepper NB, Oertel M, Rehn S, Kobe C, Eich HT (2023) Modern PET-guided radiotherapy planning and treatment for malignant lymphoma. Semin Nucl Med 53:389–399. https://doi.org/10.1053/j.semnuclmed.2022.09.001

Article  PubMed  Google Scholar 

Picardi M, Cavaliere C, Pepa DR, Nicolai E, Soricelli A, Giordano C, Pugliese N, Rascato MG, Cappuccio I, Campagna G, Cerchione C, Vigliar E, Troncone G, Mascolo M, Franzese M, Castaldo R, Salvatore M, Pane F (2021) PET/MRI for staging patients with hodgkin lymphoma: equivalent results with PET/CT in a prospective trial. Ann Hematol 100:1525–1535. https://doi.org/10.1007/s00277-021-04537-5

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sher AC, Seghers V, Paldino MJ, Dodge C, Krishnamurthy R, Krishnamurthy R, Rohren EM (2016) Assessment of sequential PET/MRI in comparison with PET/CT of pediatric lymphoma: a prospective study. Am J Roentgenol 206:623–631. https://doi.org/10.2214/AJR.15.15083

Article  Google Scholar 

Specht L, Berthelsen AK (2018) PET/CT in radiation therapy planning. Semin Nucl Med 48:67–75. https://doi.org/10.1053/j.semnuclmed.2017.09.006

Article  PubMed  Google Scholar 

Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A (2014) Modern radiation therapy for hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol 89:854–862. https://doi.org/10.1016/j.ijrobp.2013.05.005

Article  Google Scholar 

Spick C, Herrmann K, Czernin J (2016) 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients. J Nucl Med 57:420–430. https://doi.org/10.2967/jnumed.115.158808

Article  PubMed